

EMA/482304/2024

European Medicines Agency decision

P/0364/2024

of 25 October 2024

on the acceptance of a modification of an agreed paediatric investigation plan for pridopidine (hydrochloride), (EMEA-003174-PIP01-21-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0364/2024

of 25 October 2024

on the acceptance of a modification of an agreed paediatric investigation plan for pridopidine (hydrochloride), (EMA-003174-PIP01-21-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0546/2022 issued on 30 December 2022 and the decision P/0496/2023 issued on 1 December 2023,

Having regard to the application submitted by Prilenia Therapeutics B.V. on 3 June 2024 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 6 September 2024, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

¹ OJ L 378, 27.12.2006, p.1, as amended.

² OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for pridopidine (hydrochloride), capsule, hard, oral use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Prilenia Therapeutics B.V., Gooimeer 2-35, 1411DC - Naarden, Noord-Holland, The Netherlands.

EMA/PDCO/283172/2024
Amsterdam, 6 September 2024

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA-003174-PIP01-21-M02

Scope of the application

Active substance(s):

Pridopidine (hydrochloride)

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of Huntington disease

Pharmaceutical form(s):

Capsule, hard

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Prilenia Therapeutics B.V.

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Prilenia Therapeutics B.V. submitted to the European Medicines Agency on 3 June 2024 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0546/2022 issued on 30 December 2022 and the decision P/0496/2023 issued on 1 December 2023.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 8 July 2024.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition:

Treatment of Huntington disease

The waiver applies to:

- the paediatric population from birth to less than 2 years of age;
- capsule, hard, oral use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) are not feasible.

2. Paediatric investigation plan

2.1. Condition:

Treatment of Huntington disease

2.1.1. Indication targeted by the PIP

Treatment of adolescent-onset juvenile Huntington disease (JHD)

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 2 years to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Capsule, hard

2.1.4. Measures

Area	Description
Quality-related studies	Study 1 Development of an age appropriate oral formulation.
Non-clinical studies	Study 2 (NC23-TOX-22) Definitive juvenile toxicity study in rats to evaluate the risks associated with use of pridopidine in paediatric patients with Huntington's disease (HD).
Clinical studies	Study 3 (PL101-JHDPK201) Open label, uncontrolled trial to evaluate pharmacokinetics (PK) and safety of pridopidine in children with Huntington's disease to contribute to modelling of the PK in children from 10 years to less than 18 years of age.

	Study 5 (PL101-JHD202) – added during EMEA-003174-PIP01-21-M02 Double-blind, placebo controlled trial to evaluate safety, efficacy and pharmacokinetics (PK) of pridopidine in paediatric patients from 2 years to less than 18 years of age with Huntington’s disease.
Modelling and simulation studies	Study 4 Modelling and simulation population pharmacokinetic (PK) study, to evaluate the use of the product in the treatment of juvenile Huntington’s disease in children from 2 years to less than 18 years of age with Huntington’s disease.
Other studies	Not applicable.
Extrapolation plan	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By March 2030
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

The product is not authorised anywhere in the European Community.